AB1128 METHOTREXATE MAINTENANCE THERAPY IN PSORIATIC ARTHRITIS

Background The management of psoriatic arthritis (PsA) is currently well codified. Methotrexate (MTX) remains the most frequently used DMARD in first-line treatment peripheral joint disease. Objectives We aimed to identify rate therapeutic maintenance MTX during PsA and determine date first biotherapy. Methods conducted a single-center, retrospective study including patients with involvement. Patient disease characteristics were recorded. determined tolerance profiles. recorded data related Results Twenty-two women eleven men included. mean age was 52.31±12.98 years [21-78]. duration 10.90±5.91 [1-21]. had an articular onset 68.8% cases axial 31.3% patients. Psoriasis present at diagnosis 27 (81.8%). 42.70±13.84 [19-68]. initiated for all after 3.14±2.58 months [1-12]. It prescribed orally 86.7% intramuscularly 13.3%. 7.83±5.90 1 year 100%, 2 83.3%, 5 70%. discontinued 4 adverse events: 3 digestive intolerance case liver toxicity. Biotherapy 10 (30.3%): Infliximab (2 cases), Adalimumab Etanercept (6 cases). time prescription biotherapy 4±1.6 [3-7]. indicated but not (15.2%). Causes non-prescription mainly lack social security coverage. Conclusion In our study, PsA. seems be good reflecting effectiveness. However, this certainly influenced by socio-economic factors. REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.